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1. Introduction
A safe and efficient drug carrier must offer protection to human tissues in which it is admin‐
istered as well as protection to the drugs against degradation, improve therapeutic effect,
prolong biological activity, control drug release rate, and decrease the frequency of adminis‐
tration. These characteristics could be achieved by using chitosan to prepare carriers of drugs.
It is almost the only cationic polysaccharide in nature with a great innate medical potential.
Chitosan, a cationic polymer of natural origin, is a remarkable example of an excipient which
currently has enormous potential for using in pharmaceutical dosage forms because of its
properties as polyelectrolyte with reactive functional groups, gel-forming capability, high
adsorption capacity, biodegradability and biocompatible and non-toxic to living tissues as well
as having antibacterial, antifungal and antitumor activity. These functional properties provide
suitability and extensive pharmaceutical applications such as for the preparation of drug
delivery systems (drug conjugate, micro/nanoparticles, hydrogels, emulsions, biodegradable
release system, etc.) and for regenerative medicine for many components such as proteins/
peptides, growth factors, anti-inflammatory drugs, antibiotics intended to be administered in
non parenteral routes (oral, topical, intranasal, vaginal, rectal and ocular). Interesting appli‐
cations of chitosan has been receiving considerable attention since it has been developed
systems more versatile by the incorporation of chitosan and other components in novel
systems. They have provided a strategy for the functionalization by modulating physico‐
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
chemical properties (hydrophilicity, surface charge, etc.) improving the encapsulation,
stability, and protection of drugs. The recent development of nanotechnology and the various
processes of funcionalization of chitosan have increased and improved its functionality as drug
carrier.
This work reviews the drug carrier systems using chitosan to improve and increase the delivery
of drugs for non parenteral routes. The most important properties of chitosan, the types of
systems intended to be used for non parenteral routes, the strategies for the functionalization
of chitosan systems by the incorporation of other components, advantages and limitations,
and the relevance of pharmaceutical, pharmacological and toxicological experimental studies
are reviewed in different drug carrier systems from chitosan.
2. General characteristics of chitosan
Chitosan is an abundant polysaccharide, it has the peculiarity of being the unique cationic
biopolymer of natural origin [1, 2]. It is obtained from the chitin, the most second abundant
polysaccharide in the nature [3, 4]. The wide variety of natural sources of chitosan include:
structural components of the cell walls of certain fungi, algae and bacteria species, and in the
egg shells of nematodes. Nevertheless, the principal source is the shells of mollusks and the
exoskeleton of the phylum Arthropoda such as Crustacea, Insecta, and Myriapoda subphylums
[3, 5-7]. The principal industrial source of chitosan is the chitin of the crustacean shell wastes
such as crab (10% of chitin), shrimp (22% of chitin), lobster (17% of chitin) and crawfish (36%
of chitin) [8, 9]. Although it is much less common than the natural occurrence of chitin, it is
possible to obtain chitosan directly from a natural source, e. g, the structure of certain fungi
[10]. However, chitosan is generally produced by chemical processes that involve the alkaline
deacetylation of chitin aided by thermochemical conditions or by enzymatic hydrolysis in
presence of a chitin deacetylase [2, 6, 11].
2.1. Chemical properties
The chemical structure of chitosan is ideally formed only by 2-amino-2-deoxy-β-D-glucopyr‐
anose, the deacetylated form of D-glucosamine, and chitin is ideally formed only by 2-
acetamido-2-deoxy-β-D-glucopyranose, which is the acetylated form of D-glucosamine.
However, the real found structure of chitosan, as well as the one of chitin, is a copolymer of 2-
amino-2-deoxy-β-D-glucopyranose and 2-acetamido-2-deoxy-β-D-glucopyranose, in which
both the deacetylated and the acetylated forms of D-glucosamine are randomly distributed
along the whole copolymer chain. This is the reason why chitosan comprises a wide group of
fully and partially deacetylated chitins. The two kind of D-glucosamine residues are linked by
β(1→4)-glycosidic bonds. It is accepted chitosan is composed predominantly of the deacety‐
lated form of D-glucosamine [1, 2, 4, 6, 7, 11-13]. The Figure 1 represents the chemical structure
of chitin and chitosan.
Commercial chitosans have a deacetylation degree of 85%, and its elemental composition is
44. 11 % of carbon, 7. 97 % of nitrogen, and 6. 84 % hydrogen [6]. When chitosan is obtained
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using an alkaline process, the degree of deacetylation can be controlled if the time, temperature
and the concentration of alkali and chitin are also controlled. In addition to these processing
factors, the degree of acetylation, the distribution of acetyl groups along the biopolymer chain,
and the molecular size distribution of chitosans change depending of the source of chitosan.
All these factors determine chitosan physicochemical and biological properties [13, 14].
Chitosan is distinguished by its solubility in dilute aqueous acid solutions derived from its
polycationic character [9] and its insolubility in most solvents. In function of deacetylation
degree, a chitosan polymer becomes soluble in dilute acidic medium; the minimum deacety‐
lation level for solubilizing is 40-60%. The solubility of the polymer, the inter-chain interactions
due to hydrogen bonds and the hydrophobic character of the acetyl group are affected by the
distribution of N-acetyl groups along the biopolymer chain [13]. The solubility of chitosan is
also affected by the formation of crystalline structures as a result of intra- and inter-macro‐
molecular hydrogen bonds in the solid state; crystalline domains appear to be the main factor
limiting for chitosan aqueous solubility [15]. Between acidic and neutral pH conditions,
chitosan develops positive net charges because of its polycationic nature [9, 13]. Chitosan is
positively charged due to primary amino groups, the magnitude of the charge density is
dependent on the degree of deacetylation, pH, and ionic strength [9]. In weakly acidic aqueous
solutions of inorganic acids (phosphoric and sulfuric acids) and organic acids (formic, acetic,
tartaric, and citric acids), amino groups are partially protonated, while a total protonation is
reached at pH 4. 0 [15]. Another chemical characteristic of chitosan is its metal binding capacity
attributed to its chelating ability of the amine groups [5]. Table 1 shows some intrinsic
(structural characteristics of chitosan) and extrinsic parameters that affect some functionality
parameters [16-18].
Figure 1. Chemical structures of chitin and chitosan and their monomers: a) 2-acetamido-2-deoxy-β-D-glucopyranose
or β-D-GlcNAc and b) 2-amino-2-deoxy-β-D-glucopyranose or β-D-GlcN.
2.2. Physical properties
Physical properties of chitosan depend of factors as the molecular weight distribution, the
acetylation degree and the source of chitosan. In Table 2 are listed some physical properties of
reported in scientific literature and commercial chitosans from different sources [19-22]. The
solution conformation of chitosan can occur as rod-like, spherical or random coil conforma‐
tions in function of the molecular weight distribution and degree of acetylation; the molecular
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mass affects the intrinsic viscosity and radius of gyration [23] while the degree of acetylation
determines in turn the electric charge which is directly related to the solution conformation of
chitosan [20]. When the charge on the chitosan chain increases, its conformation in solution
expands and the viscosity increases substantially [24].
Functionality
parameter
Intrinsic and extrinsic chitosan
factors that affect its
functionality
Correlation between chitosan functionality parameters
and structural characteristics
Viscosity •Molecular weight
•Deacetylation degree
•Presence of contraions
•pH
•Solvent
•Viscosity of the chitosan solutions is affected by the
presence of the amino groups with a pKa value of 6. 3 (as a
strong base its polielectrolyte nature affects the
hydrodynamic ratio in solution) [16].
Hydrogels
formation
•Molecular weight
•Deacetylation degree
•Chitosan concentration
•Presence of contraions
•pH
•Temperature
•At pH above 7 and at low temperatures (≈25ºC) the
hydrogels are greatly swollen [17].
•Hydrogels are more compact and irregular when the
deacetylation degree (D.D.) of chitosan is increased [18].
Biodegradation •Molecular weight
•Deacetylation degree
•Lower molecular weights leads to a faster biodegradation
rates than higher molecular weights.
•Deacetylation degree is determinant, increasing the
presence of charged moieties leads to faster degradation
rates.
Solubility •Acid concentration
•Ionic strength
•Deacetylation degree
•Chitosan is soluble at a higher concentration of hydrogen
ions (below at a pH of 6) [16].
Table 1. Correlation of intrinsic properties and extrinsic factors that affect its functionality and structural
conformation
Source Housefly larvae SeaCure+210 Crawfish Shrimp shells
Color White White White to beige
Appearance Powder Powder Powder/chips
Granularity (mm) 0. 245
Ph 6. 96
D. D. (%) 83. 1 89 73 >75
Viscosity 347 mPa. s 540 ml/g [η] 563. 7 cP
Density (g/ml) 1. 72 0. 23 (tapped) 0. 15-0. 3
Reference [19] [15] [21] [22]
Table 2. Some physical properties of reported in scientific literature and commercial chitosans
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Rheological properties of chitosan solutions are independent of the ionic strength and the pH,
this behavior can be related to the fact that the ionic strength within certain range does not
affect the conformation in solution [23, 25]. In organic acid solutions as acetic acid ones, the
viscosity curves for chitosan solutions consist of two distinct viscosimetric behaviors, the first
one is a Newtonian zero-shear viscosity region and second one is a shear rate dependent
apparent viscosity region. An increase in chitosan concentration produces a pseudoplastic
behavior, i. e., a higher shear rate dependence of viscosity [9] while at a lower concentration
exhibits a shear thinning behavior [25]. The pseudoplastic behavior is explained because as
the polymer concentration increased, the freedom of movement of the individual chains
becomes more restricted due to the correspondingly increased number of entanglements
between chitosan chains [9]. Table 3 shows viscosities of various chitosan samples [21, 26-29].
Because chitosan undergoes acid-catalyzed hydrolysis, chitosan presents an irreversible
decrease in viscosity in dilute acid medium [28], the degree of hydrolysis depends on the
molecular weight and degree of acetylation: the higher the values of both parameters, the
quicker decrease in the viscosity and, consequently, in the viscosity-average molecular weight
[29].
Due to its degradation in acidic media, chitosan dissolved quickly after swollen in gastric juice
and could not achieve sustained release in the gastrointestinal tract [30]. In order to obtain
chitosan derivatives with new functionality and to extend its uses in a greater number of
pharmaceutical applications, chitosan has been subjected to various chemical modifications.
The chitosan structure has been modified through trimethylation, N-succinylation, thiolation,
azidation, sugar-modified chitosan, chitosan-dendrimer hybrids, cyclodextrin-linked chito‐
sans, crown-ether-bound chitosan, chemical grafting of chitosan, enzymatic modification of
chitosan. These reactions yield chitosan-based derivatives that retain the biodegradability and
non-toxicity characteristic of chitosan [1].
Chitosan is able to form physical gels, these gels retain the main properties of this polysac‐
charide, in particular, biocompatibility. The process of gel formation depends on the initial
concentration of the polymer and charge density, which is determined by the degree of
deacetylation [31]. The degree of hydration of chitosan hydrogels are affected by the molecular
weight of chitosan [32]. Chitosan hydrogels have been investigated as potential vehicles for
targeted drug delivery [15] specially seems to be suitable for sustained-release drug [32, 33].
Polycationic character of chitosan opens the possibility for interactions with negatively
charged molecules (anions and polyanions) [34] and allows the forming of polyanion-chitosan
complexes with polyanions such as heparin, carboxymethylcellulose, carrageenan, alginate,
Pluronic, dextran sulfate, and xanthan have been produced [35-51]. The complexes formed by
chitosan with other polymers can be divided into hydrogen bonding complexes, polyelectro‐
lytes complexes, coordination complexes and self-assembly complexes based on dominant
intermolecular interactions [52]. Some chitosan-based non-stoichiometric polyelectrolyte
complexes are soluble at physiological pH and ionic strength [53], because polyelectrolyte
complexes are formed in aqueous solutions, it should be taken into account molecular
information as the molecular weight of chitosan, its mass distribution, the degree of deacety‐
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lation, the location of free and acetylated amino groups in the polymer chain, chain length,
and conformation of molecules in solution [34]. The synthesis mechanism of chitosan-
polyanions complexes can be the result of changing the chemical structure of component
polymers, such as molecular weight, flexibility, functional group structure, charge density,
stereoregularity, and compatibility, as well as synthesis conditions: pH, ionic strength,
concentration, mixing ratio, and temperature [30].
Preparation method D. D(%) M. W. (kDa) Viscosity Reference
Oxidative fragmentation (1% NaNO2) of
chitosan 91. 3 659. 4
1. 05 dL/g (intrinsic, in 0. 25 mM
acetate buffer, 0. 05-0. 3 g/dl of
chitosan, 25°C)
[26]
Oxidative fragmentation (4% NaNO2) of
chitosan 90. 19 864. 2
0. 21 dL/g (intrinsic, in 0. 25 mM
acetate buffer, 0. 05-0. 3 g/dl of
chitosan, 25°C)
[26]
1% NaOH, 21 hr, 4% HCl, 2 hr 75. 9 Notdetermined
830 cP (1% acetic acid, 1%
chitosan) [27]
4% HCl, 2 hr, 1% NaOH, 21 hr 76. 3 Notdetermined
2919 cP (1% acetic acid, 1%
chitosan) [27]
Demineralization 1N HCl, 30 min, room
temperature after decolorization 0. 315%
NaOCl, 5min, room temperature
73 10. 59 563. 7cP(1% acetic acid, 1%chitosan, 25°C) [21]
Deproteinization 3. 5%NaOH, 2hr, 65°C
after decolorization 0. 315% NaOCl, 5min,
room temperature
70 9. 63 444. 9 cP1% (1% acetic acid, 1%chitosan, 25°C) [21]
Table 3. Viscosity of chitosan related to deacetylation degree (D. D. ), molecular weight (M. W. ) of chitosans produced
by different methods.
In addition to the electrical charge, dipole-dipole interactions, as well as hydrogen and
hydrophobic bonds are determinant for the formation of complexes with polyanions [34]. As
a matrix for releasing drugs, chitosan complexes must allow the controlled release either
modulating tissue drug levels or spatially-placing (or temporarily-placing) a drug in some
region of the body to maintain efficacy and stability of drugs within the matrix. For drug
delivery systems for gastrointestinal, respiratory, ophthalmologic, cervical, and vaginal
routes, the mucins are hydrophilic saline gels that are thickened by natural anionic glycopro‐
teins. Here, a cationic polymer as chitosan is ideal [52].
2.3. Biological properties
Chitosan has excellent properties such as hydrophilicity, biocompatibility, biodegradability,
antibacterial and adsorption applications, and a very low toxicity [54-57]. The biocompatibility
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of chitosan is generally regarded as the ability of the newly developed material to interact with
living cells, tissues, or organs by not being toxic or injurious and not triggering immunological
reactions or rejections while functioning appropriately in vitro and in vivo [57]. Accordingly
the features mentioned above, besides the chitosan being used for drug delivery, is used in
tissue engineering, gene delivery, nasal drug and vaccine delivery [58]. The formulation of
chitosan with a drug may alter the pharmacokinetic and biodistribution profiles, and for
pharmaceutical applications it is necessary to take in account the route of administration, its
concentration, contact time and cell types that enter in contact with chitosan or chitosan
complexes [58-63]. In Table 4 are listed some biological and toxicological properties of chitosan
in several biological systems [64-75].
Due to its good biocompatibility and biodegradability properties, chitosan provides a useful
excipient for mucoadhesive drug delivery systems in order to prolong the mucosal residence
time. An inconvenient issue about chitosan, it is that glucosamine from shellfish may not be
suitable for allergic people to shellfishes [10]. Although chitosan has not yet been related
directly to cases of allergic reactions, some cosmetics or nutraceuticals products prepared with
chitosan are related to skin irritation or even anaphylaxis [21, 76, 77]. It is possible that proteins
from shellfish such as tropomyosin and arginine kinase remain as residues on the chitosan and
chitin, being these substances responsible for such allergic reactions [78]. As a result of this
review, no allergenic reactions produced to nasal membranes have been found reported. Arai
et al. found that chitosan has an LD50 comparable to sucrose of >16 g/kg in oral administration
to mice [79]. No oral toxicity was found in mice treated with 100 mg/kg chitosan nanoparticles
(80 kDa, 80% DD) [80]. Exposure of rat nasal mucosa to chitosan solutions at 0. 5% (w/v) over
1 h caused no significant changes in mucosal cell morphology compared to control [81]. From
most studies reported it appears that chitosan shows minimal toxic effects and this approves
its adoption as a safe material in drug delivery. Others authors studied the safety of a chitosan
bandage in shellfish allergic patients (shellfish allergy prevalence of 2. 8% in adults) showing
that all subjects tolerated the bandage without reaction. Although larger cohort studies should
be considered, the results from this study are encouraging and consistent with two previous
studies demonstrating the safety of other chitin-derived products in patients allergic to
shellfish [82].
An important aspect in the use of polymers as drug delivery systems is their metabolic fate in
the body or biodegradation [54]. Degradation of chitosan by thermal, acidic, enzymatic, and
irradiation process have been reported [28, 29, 60-63, 83- 85]. In general, both rate and extent
of chitosan biodegradability in living organisms are dependent on the degree of deacetylation
[54]. Enzymatic degradation of chitosan is sensitive to the supermolecular structure of the
polymer [83], in human body lisozyme produces the hydrolysis of chitosan [86]. Aminosugars
released as a result of its biodegradation can be used in the metabolic pathways of glycosa‐
minoglycans and glycoproteins in the body [87, 88]. In the stomach, some chemical degradation
is wide catalysed by gastric acid [54], but it is not hydrolyzed by human digestive enzymes
[69], its lack of absorption in the human body provides chitosan a function as dietary fiber [56].
In the case of the systemic absorption of hydrophilic polymers such as chitosan, they should
have a suitable Mw for renal clearance [54].
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D. D (%) M. W. Concentration ofchitosan Reference
Biological activity
Antitumor activity against
HepG2, A549, and PC3 model
tumor cell
100
87. 5
Pentamers
Octamers IC50 < 50 μg·mL−1 [64]
Prevent leakage and bleeding
from lung punctures
99
98
230 kDa
300 kDa
2. 3% (w/v)
2. 3% (w/v) [65]
Reduction of 25-30% in
plasmatic cholesterol in rats 5% of the diet [66]
Decreasing of fat digestibility,
mineral absorption and vitamin
E level in rats fed with high-fat
diets
90 Not specified 50g/100g of solids [67]
Prevention the symptoms of
isoprenaline-induced
myocardial infarction in rats
85-87 750kDa 2% of the diet for 60days [68]
Reduction of body weight and
plasma triacylglycerol
concentration in mice
Not specified 46 kDa 300 mg/Kg dailyadministrated [69]
Antibacterial activity
Against E. coli 20%11%
55, 155
5, 300
50-100 ppm
2500-10000 ppm [70, 71]
Against L. monocytogenes 10 (56 kDa) 5, 150 1000 ppm [72]
Against S. typhimurium 15-25% (150 kDa) 5, 150 1000 ppm [72]
Maximum inhibition of
absorption of Streptococcus
sobrinus by hydroxyapatite
(anti-plaque activity)
50-60% 5-6 250 ppm [73]
Toxicity
Aspartic acid salt of chitosan in
B16F10 cells 78% <50 (IC50)2. 50 mg/mL [74]
Aspartic acid salt of chitosan in
Caco-2 cells 87% 20, 45, 200, 460
(IC50)670, 650, 720
mg/mL [75]
Table 4. Some biological and toxicological properties of chitosan related to deacetylation degree (D. D. ), molecular
weight (M. W. ) and its concentration in several biological systems.
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The administration of chitosan in humans has been extensively studied (Table 5) [89-94]. The
chitosan exhibits a hypocholesterolemic effect, the administration of chitosan, regardless of
their molecular weight, coupled with ascorbic acid, produce a decreased fat absorption. When
chitosan enters in contact with gastric fluids, forms a gel that traps lipids preventing their
absorption in the intestine. Sodium ascorbate enhances the gelling and flexibility of chitosan,
increasing the amount of fat that is stuck [95]. By blocking the absorption of fat is inhibited the
atherosclerotic plaque formation, reducing the risk of atherosclerosis in hypercholesterolemic
persons [88], besides that no deterioration occurs in the intestinal mucosa causing anti-
hypercholesterolemiants as cholestyramine [96].
Fat absorption depends on the degree of deacetylation and the viscosity of chitosan. The greater
degree of deacetylation and a high viscosity of the chitosan cause a higher absorption of dietary
fat [66]. Chitosan also reduces cholesterol, urea and creatinine, and increases of hemoglobin
levels, which may be used as coadyuvate in the treatment of patients with kidney failure [89].
Chitosan can cause wound healing and fibrosis decreasing mortality genitourinary surgery,
and produce a hemostatic effect, which is attributed to the interaction between the cell
membrane of the erythrocytes and chitosan, being this interaction independent of the classical
cascade of coagulation [97].
Health problem Treatment Effect Reference
Renal failure 45 mg/tablet per 12 weeks Reduction of urea, cholesterol,creatinine levels in serum. [89]
Obesity
Four tablets, 400 mg/tablet, per
day with low calorie diet for 4
weeks
Variable adverse effects in 5% of
treated subjects [90]
Overweight
0, 4. 5, 6. 75 g of chitosan per day
for eight weeks, no dietary
restrictions
No effect on serum content of
vitamins A, E, D, alpha carotene, beta
carotene. Modest reduction in
plasma cholesterol concentrations
[91]
Hepatocellular carcinoma Local percutaneous Ho-166/chitosan complex injections
Complete tumor necrosis in 77. 5%
of treated patients [92]
No health problems 5 g of chitosan Prevention of blood pressure after ahigh in salt meal [93]
Hypercholesterolemia 1. 2 g of chitosan per day, nodietary restrictions
Mild reduction in total and LDL
cholesterol, few adverse effects
observed
[94]
Table 5. Effects of chitosan and complexes containing chitosan administrated on humans with different health
problems.
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2.4. Chitosan and chitin biodegradability
Biodegradation of chitosan and chitin implies the cleaving of the β(1→4)-glycosidic bond
between the two kind of D-glucosamine residues that form its chemical structure. Biodegra‐
dation of chitosan has been assessed by enzymatic methods using enzymes from different
sources. The lysozyme (EC 3. 2. 1. 17) is an enzyme which degrades chitosan and chitosan-
conjugates by cleaving the β(1→4) bonds between N-acetyl-D-glucosamine residues; lysozyme
also degrades β(1→4)-glycosidic bonds between the N-acetylmuramic acid and N-acetyl-D-
glucosamine residues in peptidoglucan [98]. Lysozyme exists in various human body fluids
and tissues with concentrations from 4 to 13 mg/L in serum and from 450 to 1230 mg/L in
human tears [99]. The rate of biodegradation of chitosan by the lysozyme is affected by the
degree of deacetylation; initial degradation rates increase with a decreasing degree of deace‐
tylation.
Some chitosan derivatives exhibit a faster degradation rate than chitosan, for example with
the increasing of the molar ratio of glycolic acid to chitosan of poly(glycolic acid) grafted
chitosan the rate of degradation gradually increased [100].
Chitin polyphorms exhibit different rates of degradation. Lysozyme degrades β-chitin more
readily than α-chitin due to the weak intermolecular forces of the latter. In β-chitin the degree
of deacetylation is decisive for the degradation behavior of chitin [101].
Chitinases are enzymes present in fungi, insects, and bacteria, these enymes degrades chitin
to olygosaccharides. In general, microbial endo-chitinases hydrolyze β(1→4)-glycosidic bonds
randomly. Chitinases isolated from different organisms have widely different characteristics.
In human the presence of chitinases is associated to allergic reactions. Human chitinases with
enzymatic activity have been identified, but they have not been investigated with regards to
the degradation of chitosan and/or its derivatives [52].
2.5. Toxicological properties
Biodistribution, in vivo and in vitro toxicity using various chitosans of different molecular
weights and degrees of deacetylation and derivatives would provide data that could help
correlate chitosan's structure and safety profile [48]. Some derivatives increase in toxicity and
any residual reactants must be carefully removed [49]. In laboratory mice, the LD50 of chitosan
is similar to that of salt or sugar (16 g/kg of body weight) [50].
3. Drug carrier systems using chitosan intended to be used for non
parenteral routes
A considerable amount of work has been published on chitosan and its potential use in drug
delivery systems. In recent years considerable research has been focused on noninvasive
routes, such as mucosal (oral, buccal, nasal, pulmonary and vaginal) and (trans)dermal.
Chitosan has a cationic character because of its primary amino groups. These primary amino
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groups are responsible for properties such as controlled drug release, mucoadhesion, in situ
gellation, transfection, permeation enhancement, and efflux pump inhibitory properties.
The mucoadhesive properties are also based on its cationic character. The mucus gel layer
exhibits anionic substructures in the form of sialic acid and sulfonic acid substructures. Based
on ionic interactions between the cationic primary amino groups of chitosan and these anionic
substructures of the mucus, mucoadhesion can be achieved. In addition, hydrophobic
interactions might contribute to its mucoadhesive properties. Moreover, several studies have
shown the effects of chitosan systems for the drug delivery. The molecule has been widely
used in a variety of pharmaceutical multipurpose excipients capable of increasing aqueous
solubility and drug stability [102].
3.1. Nasal delivery systems
Owing to nasal obstacles such as low membrane permeability, a short local residence time,
and high turnover rate of a secretion in nasal cavities, the bioavailability of nasally adminis‐
tered drugs is often comparatively poor [103]. In order to overcome those problems, chitosan
particles or polyelectrolyte complexes have been studied for nasal delivery of therapeutic
proteins [104-106]. It was found that insulin loaded chitosan nanoparticles enhance nasal drug
absorption to a greater extent than relevant chitosan solutions.
Chitosan has been also used recently via intranasal in many studies particulary in vaccines as
a potent mucosal adjuvant. In a study, the matrix protein 1, which is highly conserved in all
influenza A strains, was purified and used for immunization (twice at an interval of 3 weeks)
of BALB/c mice by intranasal drip using chitosan as adjuvant to test the efficacy as vaccine.
The results showed that nasal administration of 100 μg of the matrix protein 1 in combination
with chitosan could not only completely protect the mice effectively against the homologous
virus (H9N2) but also protect 70% and 30% of the mice against the heterologous H1N1 and
H5N1 viruses, respectively, indicating that the matrix protein 1 is a candidate antigen for a
broad-spectrum influenza virus vaccine and the adjuvant chitosan significantly improved the
efficacy of the vaccine. This vaccine could provide effective protection against unknown
influenza virus infection in future [107].
Microparticles (with suitable range for vaccine delivery) and gels using chitosans with
different molecular weight and solubility as adjuvant/delivery system for mucosal (nasal)
immunization against bovine herpes virus 1(BHV-1) showed that when the virus was incor‐
porated into microparticles, the particle size was increased (p < 0. 05). Narrower particle size
distribution was obtained with water soluble chitosan compared to that of base chitosan
particles at different molecular weights (p < 0. 05). This difference can be attributed to differ‐
ence in solubility of chitosans [108]. Similar results were reported in other studies [109-112].
With blank microparticles prepared with base chitosan at different molecular weights, the
surface appearance and morphology were observed to be similar (with a smooth surface and
spheroids). When the particles were loaded with the antigen; the surface appearance of the
microparticles was changed with the increasing molecular weight of chitosan (Figure 2). These
results suggest that antigen is entrapped within the microparticles, as well as associated with
the surface of the microparticles [108]. Similarly, increased particle size and surface roughness
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with antigen loading has been reported by other groups [113, 114]. These systems are prom‐
ising adjuvant/delivery systems for non-invasive delivery of antigen tested as well as for other
antigens.
Moreover, the nasal administration of vaccines can induce specific IgA antibody responses at
distant mucosal sites, including the upper and lower airway mucosa and the small and large
intestines, as well as the nasopharynx, salivary glands, genital tract, and tonsils, because of the
dissemination of antigen-specific lymphocytes in the common mucosal immune system
(immunocompetent cells in the body, such as M-cells, T-cell, B-cell, dendritic cells, and
macrophages) [114-116].
3.2. Oral delivery systems
Chitosan-based formulations have been used for the delivery of drugs to specific sites of the
body such as oral cavity, stomach, small intestine and colon. The site-specific delivery of the
drug to the oral cavity can be used to treat a number of diseases of the mouth, such as stomatitis,
periodontal disease, fungal and viral infections, and oral cavity cancers, thereby avoiding the
first pass metabolism effect. In this sense, some points should be considerate for buccal
administration of drugs, such as maintain the device in its position for many hours against
buccal motion and salivary flow, which could reduce the mucosal absorption. Consequently,
the dosage form must have good adhesive properties and show an efficient control of drug
delivery. Investigations have shown in several studies that drug release is influenced by
swelling and erosion of the matrix, whereas matrix adhesiveness can be modulated using
different mixtures of polymers, both adhesive and not. Here, investigations have reported that
the chitosan has good mucoadhesiveness and a significant enhancing effect on the permeation
of drugs across the buccal mucosa [117, 118]. The applications using chitosan include chlo‐
rhexidine loaded chitosan microparticles, which showed a determination effective of antibac‐
terial activity of chitosan from thermosensitive hydrogel (with or without drugs) or as activator
for the antibacterial process [119]. Chitosan microspheres based drug delivery is applicable
for systemic as well as for local therapy. In case of oral drug delivery, the use of microspheres
loaded with antibiotics would be beneficial for gastric diseases such as peptic ulcer [21],
Helicobacter pylori, and intestinal infections, ulcerative colitis and carcinomas [20]. On the other
hand, in many studies it has been demonstrated that chitosan-based formulations were
superior in enhancing absorption of therapeutic proteins as well as induction of antibodies
after mucosal vaccination [34-36].
With respect to the colon drug delivery, some microcrystalline cellulose core beads containing
5-aminosalicylic acid produced by extrusion-spheronization were coated with chitosan and
Aquacoat® ECD mixtures. An adequated selection of the coating thickness and the chitosan
level in the coat could minimize drug release in simulated intestinal fluid and provide zero
order release. These products could also be used to achieve controlled release of drugs in the
small intestine. Beads coated with chitosan/ Aquacoat® showed to be susceptible to the action
of rat cecal and colonic enzymes and demonstrated their potential for colon specific drug
delivery [120].
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3.3. Ocular delivery systems
Various ophthalmic vehicles, such as inserts, ointment, suspensions, and aqueous gels, have
been developed in order to lengthen the resident time of instilled dose and enhance the
ophthalmic bioavailability. Chitosan based systems have the potential for improving the
retention and biodistribution of drugs applied topically onto the eye. One of the pharmaceut‐
ical forms most investigated are the in situ gels, which have been developed to prolong the
precorneal resident time of the drug and to improve ocular bioavailability [121-126]. The
interaction and prolonged residence time of fluorescence-labelled nanoparticles prepared with
chitosan was reported showing, these colloidal drug carriers remained attached to the cornea
and the conjunctiva for at least 24 h [127]. Therefore, mucoadhesive chitosan nanoparticles
may have potential as colloidal drug delivery systems for the ocular mucosa. It was demon‐
strated the potential of chitosan nanoparticles with cyclosporine A to improve the delivery of
drugs to the ocular mucosa. Furthermore, chitosan-based colloidal systems were found to
work as transmucosal drug carriers, either facilitating the transport of drugs to the inner eye
or their accumulation into the corneal epithelia. The use of chitosan-based colloidal suspen‐
sions in vivo showed a significant increase in ocular drug bioavailability [128]. Additionally,
bioadhesive chitosan microspheres have been also studied for ophthalmic administration, in
which a high concentration of acyclovir for an extended period of time was obtained from in
vivo ocular studies on rabbits. According to the authors, in addition to its mucoadhesive
properties, chitosan is effective in retarding the rate of drug release [128].
Another interesting study reported chitosan microparticles to be administered via ophthalmic.
The in vitro release kinetics of chitosan microparticles and their in vitro and in vivo biocompat‐
ibility and cytotoxicity on retinal cells were examinated. The results showed that chitosan
microparticules were effective to obtain long-term protein or drug delivery agents to the outer
segment of the retina. Chitosan microparticles exhibited enhanced encapsulation capacity and
a better release profile than the Polyethylene glycol-Polylactic acid (PEG–PLA) microparticles
investigated previously. However, the concentration of chitosan microparticles may be critical
to determine the extent of toxicity, and the concentration required will depend on the encap‐
sulation efficiency and on the amount of protein (or drug) required to obtain a therapeutic
dose [129].
3.4. Topical/transdermal delivery systems
Transdermal drug delivery systems can deliver drugs for systemic effects through skin at
controlled rate (can be interrupted if it necessary), with the advantage of avoiding the first pass
metabolism effect [130-134]. An example of this could be obtained with the lidocaine hydro‐
chloride-loaded transdermal chitosan patches as a drug reservoir, which released the drug in
a manner prolonged at 95% chitosan degree of deacetylation [135].
In a recent study, warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal
delivery were successfully prepared by ionic gelation method. Chitosan nanoparticles were
found to be spherical, smooth and with narrow size distribution. They showed high drug
entrapment efficiency and well accepted yield. The release profile from nanoparticles showed
an initial burst effect followed by a slow and continuous release phase. The nanoparticle
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Figure 2. SEM micrographs of blank (A) and BHV-1 loaded microparticles (B) prepared with water soluble chitosan;
chitosan base-low molecular weight (50-1000 kDa): blank (C), BHV-1 loaded microparticles (D); chitosan base-medium
molecular weight (300-2000 kDa): blank (E), BHV-1 loaded microparticles (F); chitosan base-high molecular weight
(500-5000): blank (G), and BHV-1 loaded microparticles (H). This figure is reproduced with the permission [108].
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formulation enhanced the permeation of warfarin through excised rat skin in a constant and
continuous profile. Therefore, it could be concluded that this formulation enhanced the
controlled release and the permeation of warfarin, offering a promising system for the
transdermal delivery [136].
3.5. Regenerative systems
In order to regenerate some loss or damaged tissue and organ, in vitro seeding and attachment
of human cells onto a scaffold, followed by the culturing of the cells to form the new organ or
tissue must to be performance to avoid some transplantation of them. Chitosan is one of the
most exploited polymers for this application due to its known biocompatibility, biodegrada‐
bility, antibacterial and wound-healing activities. Its use in tissue engineering stems from the
capacity of chitosan (unmodified or as a derivative) to produce efficient scaffolds having
desirable characteristics such as porosity, gel forming ability and high affinity to in vivo
macromolecules [137]. Additionally, it has a structural similarity to glucosaminoglycans which
are the major component of the extracellular matrix. Recent studies, attempted to address this
issue through the conjugation of cell adhesion moieties to chitosan based materials, hence
aiming to produce more physiologically relevant scaffolds that mimic of the extracellular
matrix functions. In addition to provision of correct environment for cell growth and support,
biodegradability of the scaffold material is also important. It is preferred that the materials are
absorbed or excreted from the body without the necessity of surgical removal. The in vitro
investigation of the responsiveness of articular chondrocyte-like cells using a multimembrane
hydrogel of chitosan showed a large amount of cartilage-type matrix proteins were produced
[138]. Chitosan has been extensively used in bone tissue engineering, since it was shown to
promote cell growth and mineral rich matrix deposition by osteoblasts cells in culture [139].
Studies in order treat acute and chronic liver disease are also been investigated. Hepatoma
HepG2 cells were seeded onto the microfluidic-based pure chitosan microfibers for liver tissue
engineering applications without the use of any chemical additives. The results showed an
aggregation of these cells forming spheroids, which also had higher liver function that was
confirmed by albumin secretion and urea synthesis. This method represents a potentially
useful tool for liver tissue engineering applications [140].
4. Strategies for the functionalization of chitosan systems using other
components
Chitosan is a non-toxic, biocompatible and biodegradable polymer and has attracted consid‐
erable interest in a wide range of biomedical and pharmaceutical applications including drug
delivery, cosmetics, and tissue engineering. The primary hydroxyl and amine groups located
on the backbone of chitosan are responsible for the reactivity of the polymer and also act as
sites for chemical modification. However, chitosan has certain limitations for use in controlled
drug delivery and tissue engineering. These limitations can be overcome by chemical modifi‐
cation. In order to achieve high mucoadhesive properties, this polymer needs to exhibit also
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high cohesive properties as the adhesive bond otherwise fails within the mucoadhesive
polymer rather than between the mucus gel layer and the polymer. In case of chitosans,
however, these cohesive properties are also comparatively weak. Although they can be
strongly improved by the formation of complexes with multivalent anionic drugs, multivalent
anionic polymeric excipients, and multivalent inorganic anions, this strategy is only to a quite
limited extent effective, as the cationic substructures of chitosan being responsible for mu‐
coadhesion via ionic interactions with the mucus are in this way blocked. The combination of
chitosan with other materials appears to be a common theme in various reports. Blending with
other polymers is widely investigated. Blends with synthetic and natural polymers can imbibe
the wide range of physicochemical properties and processing techniques of synthetic polymers
as well as the biocompatibility and biological interactions of natural polymers.
A significantly improved oral bioavailability of buserelin was demonstrated with mucoadhe‐
sive polymers such as chitosan and carbomer to rats. This effect, however, could not be
observed anymore when chitosan was combined with the polyanionic carbomer in the same
formulation [141]. Trimethylation of the primary amino group of chitosan provides an even
more cationic character of the polymer. When trimethylated chitosan is additionally PEGy‐
lated, its mucoadhesive properties are even up to 3. 4-fold improved [142]. Due to the immo‐
bilization of thiol groups on chitosan, its mucoadhesive properties can also be strongly
improved, as the thiolated polymer is capable of forming disulfide bonds with mucus
glycoproteins of the mucus gel layer, placing it among the most mucoadhesive polymers
known so far [143]. In addition, as inter- and intrachain disulfide bonds are also formed within
chitosan itself, thiolated chitosan exhibits substantially improved cohesive properties.
Recently, the mucoadhesive properties of thiolated chitosans were even significantly further
improved by the preactivation of thiol groups on chitosan via the formation of disulfide bonds
with mercaptonicotinamide.
4.1. Oral drug delivery
Chitosan, the second most abundant polysaccharide next to cellulose, has been adopted as
having great potential application as a protein drug carrier for oral administration due to its
outstanding properties of non-toxicity, biocompatibility, biodegradability and low cost [144,
145]. Oral administration of drugs represents the easiest and the most convenient route of
drug delivery. Therefore, the enhancement of oral bioavailability of some drugs particular‐
ly those with poor aqueous solubility, is gaining increasing attention for successful develop‐
ment of oral treatment. Chitosan based hydrogel systems can be designed to deliver drugs
locally to the stomach or the upper part of tract to improve bioavailability. It was tested by
confocal  laser  scanning microscopy that  amoxicillin loaded pH-sensitive hydrogels  com‐
posed of chitosan and poly(g-glutamic acid) could be infiltrated in the cell–cell junctions and
interact with Helicobacter pylori infection sites for the treatment of peptic ulcer [146]. Hydro‐
gels of  chitosan and polyacrylic acids containing amoxicillin and clarithromycin showed
similar results.  Modified chitosan hydrogels loaded with metronidazole,  tetracycline and
theophylline could bypass the acidic environment of the stomach and release the loaded drug
into the intestine [147].
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Another investigation reported that the oral bioavailability of acyclovir could be improved 3-
fold and 4-fold due to the incorporation of this drug in chitosan and thiolated chitosan,
respectively. Within this study, a prolonged residence time in particular of thiolated chitosan
microparticles in duodenal and jejunum regions was observed. These data need to be con‐
firmed in human volunteers. So far, an improved oral bioavailability of various model drugs
could be shown in human volunteers for mucoadhesive formulations likely because of an
intimate contact of the delivery system with the absorption membrane and a prolonged
mucosal residence time of the delivery systems [148].
Several systems have been proposed to encapsulate insulin to improve oral insulin bioavail‐
ability, including polymeric hydrogels polymeric solid nano-particles and liposome-based
carriers [149-153]. However, limitations related to the enzymatic degradation in the gastroin‐
testinal tract and the low permeability across the intestinal epithelium are common problems
in those systems [154, 155].
Contrarily, it was reported that insulin analog can be successfully encapsulated in chitosan
microspheres with a high loading content. The quaternized groups on N-[(2-hydroxy-3-
trimethylammonium) propyl] chitosan chloride (HTCC) can protect the insulin analog from
the cross-linking reaction and maintain its activity. The positive charged chitosan micro‐
spheres also showed improved bioadhesion to the intestinal tract due to a strong interaction
with the mucus. Evaluation using an in vivo diabetic model showed an optimal reduction in
blood glucose level and compelling therapeutic effects after treatment with insulin analog
loaded chitosan microspheres, which further confirmed the feasibility of using quaternized
chitosan microspheres as insulin carriers for oral administration [156].
In case of oral drug delivery, the use of microspheres loaded with antibiotics would be
beneficial for several diseases [157]. A particular problem related to a low molecular weight
compound like ampicillin is the high permeability of the chitosan microbead matrix material.
In order to overcome these restrictions, chitosan gel beads and microspheres are generally
crosslinked chemically using glutaraldehyde or ethylene glycol diglycidyl ether [157].
However, residual glutaraldehyde and ethylene glycol diglycidyl ether in the chitosan
microspheres give rise to health concerns and can cause undesirable effects including irritation
to mucosal membranes. To solve these disadvantages of chemical crosslinking, researchers
have proposed to apply chitosan microspheres reacetylated with acetic anhydride. The re-
acetylated chitosan microspheres were able to interact closely with the gastric mucosa and to
exhibit sustained delivery of entrapped antibiotic [158].
The factors affecting drug encapsulation efficiency, particle size, surface charge, surface
hydrophilicity, pharmacokinetics and biodistribution were studied in clozapine-loaded
nanoparticles coated with chitosan, pluronic F-68, polyethylene glycol (PEG) 4000 and
polysorbate 80. The results proved that although a similarity in surface hydrophilicity,
chitosan-stealth nanoparticles showed different pharmacokinetic profile and biodistribution
behavior compared to polysorbate-stealth nanoparticles [159]. A great improvement in surface
hydrophilicity was brought by chitosan and polysorbate 80 coatings. However, the in vivo
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particle uptake by the reticuloendothelial system was less pronounced with positively charged
chitosan-stealth nanoparticles than with polysorbate 80. In another study, the thermal amide
conjugation of COO− group of EDTA with NH2 group of chitosan was employed to prepare
microparticles, which showed higher amphotericin B loading capacity, enhancement in the in
vitro dissolution performance 12-fold and a nanoemulsion was produced in the size range of
70–90 nm [160]. On the other hand, microparticles were prepared entrapping ovalbumin as a
model antigen following oral vaccination. In another investigation, methylated N-(4-N, N-
dimethylaminocinnamyl) chitosan was used to coat microparticles, which demonstrated a
greater swelling, mucoadhesive properties and a more sustained release than uncoated
microparticles. Thus, this formulation represent a useful carrier to improve the immunoge‐
nicity of oral vaccines [161].
Galactosylated trimethyl chitosan-cysteine nanoparticles were developed for oral delivery of
a mitogen-activated protein kinase kinase kinase kinase 4, siRNA to the activated macrophages. This
formulation was effective in protecting mice from dextran sulfate sodium induced ulcerative
colitis at a relatively low therapeutic dose by attenuating colonic TNF-α production. Adition‐
ally, a stability enhanced, cell binding and cellular uptake in activated macrophages, low
cytotoxicity, high transfection efficiency in vitro, and direct delivery to the focus of disease
were showed [162].
4.2. Buccal drug delivery
The buccal route is an alternative choice to deliver drugs to the application site. In addition,
this route shows high acceptance by patients. An ideal buccal delivery system should stay in
the oral cavity for hours and release the drug in a controlled way. Mucoadhesive polymers
prolong the residence time of the drug in the oral cavity [163]. Based on its mucoadhesive as
well as absorption enhancement properties, chitosan is a promising polymer to be used for
buccal delivery, such as chitosan mixed with sodium alginate, which was studied as a vehicle
in buccal tablets; while chitosan glutamate, interacted with polycarbophil and other anionic
polymers and was proposed for bilaminated films and bilayered tablets [164, 165].
Chitosan salts have different physical properties and can have different effects on mucosa
permeability [166, 167]. A combination of chitosan and Pluronic F-127 was investigated in one
study, showing that the drug release systems for via buccal was improved and demonstrating
that independently of chitosan salt type (citrate, acetate and lactate), mucoadhesion was
significantly favoured when the concentration of Pluronic F-127 in the matrix was about 30%
(w/w). Chitosan lactate gave good sustained release, controlled swelling, and higher mucoad‐
hesion when combined with Pluronic F-127 present in the matrix at the above concentration
(Figure 3). These results indicate that such a matrix could find useful application in buccal
drug delivery systems [168].
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Figure 3. Pictures of swollen matrices, containing different chitosan salt type (1—chitosan acetate; 2—chitosan cit‐
rate; 3—chitosan lactate) and different amounts of P407 [A—at about 50% (w/w); B—at about 30% (w/w); C—at
about 12% (w/w)]. The images were taken 4 h after starting the swelling study. This figure is reproduced with the
permission [168].
Other modifications such as, trimethylated chitosans seem to be promising exipients for drug
delivery systems intended for buccal mucosa applications to enhance the absorption of
hydrophilic macromolecules [169]. In another study, the potential of thiolated chitosan for
peptide delivery systems via the buccal mucosa was investigated in pigs [170]. The therapeutic
peptide PACAP was applied to pigs, and its bioavailability was determined in order to
facilitate the treatment of type 2 diabetes. Due to its strong permeation enhancing properties,
tablets based on thiolated chitosan raised continuously the plasma level of this peptide drug,
allowing for therapeutic range levels to be maintained over the whole period of application.
Furthermore, buccal bilayered devices with a mixture of nifedipine and propranolol as well
as chitosan displayed promising potential for use in controlled delivery in the oral cavity [171].
Chitosan (derivatives) can interact with mucus and epithelial cells and induced a redistribution
of cytoskeletal F-actin and the tight junction protein ZO-1 resulting in opening of cellular tight
junctions and increasing the paracellular permeability of the epithelium [172, 173]. Besides
their charge, other structural elements of these polymers likely contribute to their penetration-
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enhancing activity, since cationic polysaccharides such as quaternized diethyl aminoethyl-
dextran were ineffective as an enhancer.
4.3. Colon drug delivery
Colon specific drug delivery systems are gaining importance for use in the treatment of chronic
diseases, such as irritable bowel syndrome, inflammatory bowel disease, ulcerative colitis, and
also for the systemic delivery of protein and peptide drugs. By making use of this colon-specific
degradation, chitosan has been discovered as useful coating in order to guarantee a site specific
delivery. Radiolabelled (99mTc) tablets coated with a combination of pectin/chitosan/hydrox‐
ypropyl methylcellulose (3 + 1 + 1), for instance, were administered orally to human volunteers
[174]. Within this study, gamma scintigraphy was used to evaluate the gastrointestinal transit
of these tablets, showing that they remain intact through the stomach and small intestine. In
the colon, the bacteria degraded the coat, and thus, the tablets disintegrated. In another study,
it was developed a sustained dosage form for alpha-lipoic acid making use of ionic interactions
between this anionic drug and chitosan used as carrier matrix. Studies in human volunteers
showed a release maximum once the formulation had reached the colon [175].
Chitosan hydrogel beads coated with enteric polymer Eudragit S 100 were also investigated
to be targeted to the colon; they prevented premature drug release in simulated gastric fluid,
but delivered in the colon, because chitosan was degraded by the bacterial enzymes. Predni‐
solone, 5-aminosalicyclic acid, metronidazole, 5-fluorouracil and indomethacin are being
investigated in chitosan formulations for the same purposes [176].
Mixes are being used to obtain some characteristics on the formulations. Here, blended
chitosan with gelatin was used to improve the biological activity since (i) gelatin contains Arg-
Gly-Asp (RGD)-like sequence that promotes cell adhesion and migration, and (ii) forms a
polyelectrolyte complex [177]. Addition of gelatin affected the stiffness of 2D and 3D scaffolds,
facilitated the degradation rate and maintained the dimension in the presence of lysozyme.
The effect of blending chitosan with poly(ε-caprolactone) (PCL) also improved mechanical
properties as well as cellular support [178]. The γ-poly (glutamic acid), a hydrophilic and
biodegradable polymer, was also used to modify chitosan matrices and the γ-poly (glutamic
acid)/chitosan composite matrix was found to enhance hydrophilicity and serum proteins
adsorption, and to increase the maximum strength through addition of γ-poly (glutamic acid)
in tissue engineering applications [179]. The mechanical properties and biocompatibility also
were improved with galactosylated chitosan-based scaffolds by combining them with alginate.
The scaffolds exhibited the usual pore configurations, and the pore sizes were dependent on
the freezing pre-treatments, the molecular weight of chitosan and amount of galactosylated
chitosan [180, 181].
4.4. Pulmonary drug delivery
Powder formulations of protein-loaded chitosan nanoparticles suitable for pulmonary
delivery have been prepared by spray drying [182-184]. Moreover, insulin-loaded nanoparti‐
cles chitosan have been reported obtaining a good loading capacity (65–80%) and were fully
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recovered from the powder formulations after contact with an aqueous medium, and showed
a fast release of insulin. The biocompatibility and penetration-enhancing effects of their
chitosan powder formulations were examined in vitro using A549 and Calu-3 cells as models
for alveolar and respiratory epithelial cells, respectively [185]. The formulations exhibited a
very low cytotoxicity in both cell lines, but no effects on opening of tight junctions of the cells
were reported. Further, CLSM studies did not reveal internalization of nanoparticles which
contrasts previously reported studies [183]. The authors speculated that the total amount of
chitosan used in their study was lower than that used in other publications. Moreover, the
chitosan salt (glutamate) probably did not lose its charge after dispersing the particles in buffer
[183].
An inhalable chitosan-based powder formulation of salmon calcitonin-containing mannitol as
a cryoprotecting agent using a spray drying process was prepared. The effect of chitosan on
the physicochemical stability of the protein was examined with chromatographic and spec‐
trometric techniques [186]. The dissolution rate of the protein decreased when it was formu‐
lated with chitosan, which might be due to an irreversible complex formation between the
protein and chitosan during the drying process [183]. On the other hand, chitosan-coated
PLGA nanoparticle suspensions improved the absorption of calcitonin after pulmonary
administration aerosolized with a nebulizer. The elimination of the chitosan-coated nanopar‐
ticles from the lungs was retarded as compared to non-coated particles, most likely due to the
mucoadhesive properties of chitosan. It was shown that after pulmonary administration of the
chitosan-coated particles the pharmacological action of calcitonin was prolonged as compared
to that of the protein loaded in the non-coated nanoparticles [187]. In another study, the
potential of chitosan oligomers and polymers for pulmonary delivery of proteins was studied.
The absorption of interferon-α in rats was improved after pulmonary administration of
aqueous solutions of the oligomers and the interferon-α. Among various oligomers, glucose‐
amine hexamers at a concentration of 0. 5% (w/v) showed the highest efficacy. Chitosan
polymers were less efficient than the studied oligomers in increasing the systemic level of the
interferon-α, likely due to their lower solubility in lung fluids [188].
Interesting results were obtained with N-trimethyl chitosan powder formulations of insulin
using a drying process for pulmonary delivery [189]. The particles had an average volume
aerodynamic diameter of 4 μm suitable for peripherally pulmonary deposition. After one-year
storage at 4 °C, the particle characteristics were maintained and the insulin structure was
largely preserved [189]. Pulmonary administration of N-trimethyl chitosan–insulin micropar‐
ticles significantly enhanced the systemic absorption of insulin, with a bioavailability of about
95% relative to subcutaneously administered insulin.
It has been studied the development of a novel nanocarrier consisting of Lipoid S100 and
chitosan or glycol-chitosan for the systemic delivery of low molecular weight heparin upon
pulmonary administration. These nanosystems, formed by ionic gelation technique, provided
both sufficient entrapment efficiency and mucoadhesive properties. Aerosolization of these
formulations indicated that heparin could be delivered to the lung. Overall, these nanocarriers
might have a use potential for systemic delivery of low molecular weight heparin as compared
to free drug with a therapeutic potencial effect for the treatment of pulmonary embolism and
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other thromboembolic disorders [190]. The potential to deliver ofloxacin directly to alveolar
macrophages via the respiratory route was enhanced from loaded glutaraldehyde-crosslinked
chitosan microspheres in comparison with the ofloxacin powder. It suggests that chitosan
microspheres are efficient delivery system of ofloxacin to cure tuberculosis [191].
4.5. Intranasal drug delivery
Chitosan-coated gold nanoparticles have been investigated for mucosal protein delivery [192].
Chitosan was used as a reducing agent in the synthesis of gold nanoparticles and also as a
mucoadhesive and penetration enhancer. Insulin was efficiently adsorbed (∼50%) through
electrostatic interaction onto the surface of the coated nanoparticles and they were colloidally
stable for 6 months. Intranasal administration of these nanoparticles in diabetic rats showed
an improved pharmacodynamic effect as evidenced by higher reduction in blood glucose
levels as compared to insulin-loaded sodium borohydride gold nanoparticles [192].
In another study nanoparticles consisting of chitosan and negatively charged cyclodextrin
sulfobutylether-β-CD or carboxymethyl-β-CD derivatives were prepared and characterized
[104]. It was demonstrated that chitosan– sulfobutylether-β-CD–insulin nanoparticles induced
lower TEER values of Calu-3 cells than chitosan–carboxymethyl-β-CD–insulin nanoparticles.
However, both insulin-loaded nanoparticles showed similar effects on reduction of rats'
plasma glucose levels upon intranasal administrations. It should be noted that, the plasma
insulin concentrations of the treated animals which may give better indications in absorption
enhancement properties of the formulations, were not determined [104]. Chitosan has been
investigated as auxiliary agent in nasal drug delivery systems [193] due to mucoadhesive
properties improving significantly nasal uptake of isosorbide dinitrate due to the co-admin‐
istration of chitosan in rats [194]. In the same study, they showed a minor cilio-inhibiting effect
of the polymer. In addition, fentanyl nasal spray formulations with pectin, chitosan, and
chitosan–poloxamer 188 were developed for clinical evaluation to provide rapid absorption
and subsequently increased bioavailability. The study was conducted in 18 healthy adult
volunteers and revealed significantly increased systemic exposure as well as reduced times to
peak plasma values for all formulations compared with oral transmucosal fentanyl citrate
lozenge [195].
Recently, formulations prepared with chitosan and Pluronic F-127 as nasal delivery vehicles
of vaccines have been reported [116, 196, 197]. In a study, some mice Balb/c mice were
intranasally immunized with the antigen tetanus toxoid in the presence of chitosan, Pluronic
F-127/chitosan or lysophosphatidylcholine (LPC) showing that the antigen specific IgA
response in the nasal and lung washes of these animals had a significant increase in anti-
tetanus toxoid mucosal IgA response in the group of mice immunized and boosted intranasally
with Pluronic F-127/chitosan, enhancing the systemic and mucosal immune responses
compared with those in the control groups. Successful mucosal vaccination is therefore largely
dependent on the development of effective mucosal adjuvants. As it is well known, the
adaptive humoral immune defense at the mucosa is mediated by the antibodies IgA that in
mucosal secretions binds to the microbes and toxins present in the lumen and neutralize them
by blocking their entry into the host [198, 199]. This nasal vaccine could induce not only
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systemic IgG antibody responses but also mucosal IgA antibody responses, which results in
two layers of immune defense against infectious diseases. So, this study showed that the
system represents a novel nasal vaccine delivery system to enhance immune response [200].
Important effects in the nasal delivery of vaccines were found, when the Bordetella bronchisep‐
tica antigen was included in the chitosan microspheres prepared with Pluronic F-127, which
was used as a stabilizing and immunomodulating agent [115]. In the in-vitro release study, a
greater amount of the antigen was released from the chitosan microspheres prepared in the
presence of Pluronic F-127 than from only chitosan microspheres, due to the hydrophilic
property of poloxamer. The mice intranasally immunized with the microspheres using
Pluronic F-127, showed higher IgA antibody titers against the antigen in their mucosal
secretions (nasal washes and saliva) than the mice intranasally immunized with microspheres
containing only the antigen. This study suggested that chitosan microspheres prepared in the
presence of Pluronic F-127, could enhance the nasal delivery of a variety of clinically useful
antigens in vaccination schemes. Besides the enhanced immune responses, advantages of this
system include the easy preparation method, which only involved simple mixing by the ionic
gelation method with tripolyphosphate or by the emulsion-crosslinking method employing
glutaraldehyde avoiding extreme conditions such as heating and organic solvent which might
result in the denaturation of protein antigens [115, 201].
Another  objective  was  obtained  with  leucine-enkephalin  loaded  N-trimethyl  chitosan
nanoparticles, which were evaluated as a brain delivery vehicle via nasal route and pre‐
pared  by  ionic  gelation  method.  The  permeability  of  Leucine-enkephalin  released  from
nanoparticles was 35 fold improved from the nasal mucosa as compared to Leucine-enkepha‐
lin  solution.  Fluorescent  microscopy  studies  of  brain  sections  of  mice  showed  higher
accumulation  of  fluorescent  marker  NBD-F  labelled  Leucine-enkephalin,  when  adminis‐
tered  nasally  by  N-trimethyl  chitosan  nanoparticles,  while  low  brain  uptake  of  marker
solution  was  observed.  It  was  conclude  that  N-trimethyl  chitosan  nanoparticles  could
generate a significant improvement of bioactive Leucine-enkephalin levels in the brain when
is intranasally administered [203].
4.6. Ocular drug delivery
Chitosan is a suitable material for the design of ocular drug delivery systems due to its nontoxic
character, permeation enhancing properties, and physicochemical characteristics. Chitosan-
based formulations used for ophthalmic drug delivery are hydrogels [203], nanoparticles [127],
and coated colloidal systems [204]. Chitosan as well as Pluronic F-127, has recently been
proposed as a material with a good potential for ocular drug delivery, since their solutions
were found to prolong the corneal residence time of antibiotic drugs and nanocapsules coated
with chitosan were more efficient to enhance the intraocular penetration of some specific drugs
[205]. Making use of their in situ gelling properties, the formulations can be applied and
distributed on the ocular surface in almost liquid form thereafter transforming into the gel
status [203]. A combination of polycaprolactone nanocapsules as ocular carriers with the
advantages of the cationic mucoadhesive chitosan and poly-L-lysine as coating was per‐
formed. Even though poly-L-lysine and chitosan displayed a similar positive surface charge,
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only chitosan-coated nanocapsules enhanced the ocular penetration of indomethacin with
respect to uncoated nanocapsules. The authors suggested that an undetermined property of
chitosan was responsible for this enhanced uptake [204].
In other studies chitosan-alginato microspheres or beads were investigated for the encapsu‐
lation of several drugs, proteins, cells and oligonucleotides, with promising results [206-211].
The complex has biocompatible and biodegradable characteristics, and limits the release of
encapsulated materials more effectively than either alginate or chitosan alone [212]. A further
advantage of this delivery system is its non-toxicity permitting the repeated administration of
therapeutic agents. In another study, chitosan-sodium alginate nanoparticles entrapping
gatifloxacin (a broad-spectrum antibacterial agent used in the treatment of ocular infections)
were successfully formulated. The results showed that the drug was released over a period of
24 hours in a sustained release manner, primarily by non-Fickian diffusion. This new formu‐
lation is a viable alternative to conventional eye drops by virtue of its ability to sustain the
drug release, for its ease of administration because of reduced dosing frequency resulting in
better patient compliance [213].
4.7. Topical/transdermal delivery systems
Some mixes of polymers using chitosan could be used to prepare thermosensitive hydrogels
which were a good choice to reduce local irritation in the skin caused by conventional
transdermal patches (40 % of application-site skin reaction) due to components of the patch
(acrylic adhesive, polyester, polyurethane, and silicone). Therefore, these formulations can also
provide advantages for particular applications as it is transformed from a liquid to a gel when
administered topically [214]. Additionally, modifications in the delivery of drugs could be
achieved, such as that obtained for a hydrogel patch composed of chitosan and starch devel‐
oped for cosmetic applications, in which a rapid curcumin release rate was observed [215].
4.8. Regenerative systems
Amino acid grafted chitosans posses a great potential for application in these biomedical fields,
whereby a combination of the properties of chitosan and those belonging to different amino
acid moieties could produce materials with synergetic properties. Moreover, this conjugation
can enhance some properties of chitosan, such as its antimicrobial activity, which are important
in the area of tissue engineering such as wound healing [216]. Many tissue analogs including
cartilage, bone, liver, and nerve have been prepared using this engineering technology.
Systems of blood clots based in chitosan–glycerol phosphate disodium salt were purposed
since bleeding has been identified as an initiating event in post-surgical repair and it was
hypothesized that microfracture-based repair could be improved by stabilizing the clot formed
in the lesion with chitosan that is thrombogenic and actively stimulates the wound-healing
process [217]. These systems were applied as implants to marrow-stimulated chondral defects
in rabbit cartilage repair models, where they induced greater fill of chondral defects with repair
of tissue compared to marrow-stimulation alone [218]. In another investigation, a chitosan–
hydroxyapatite multilayer nanocomposite with high strength and bending modulus rendering
the material suitable was prepared for possible application as an internal fixation of long bone
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fractures [219]. A series of chitosan-tricalcium phosphate composite scaffolds were developed
for the same purpose using freeze-drying process, which provided macroporous composite
scaffolds with different pore structures. The biocompatibility, evaluated subcutaneously on
rabbits indicated that these scaffolds can be utilized in non-loading bone regeneration [220].
The use of biomimetic hydroxyapatite/chitosan–gelatin network composites in the form of 3D-
porous scaffolds improved adhesion, proliferation and expression of rat calvaria osteoblasts
on these systems [221]. Recently, a scaffold with calcium phosphate cement and chitosan fibers
with improved resistance to fatigue and fracture was used to harvest human umbilical cord
mesenchymal stem cells without an invasive procedure that is commonly required when
studying bone marrow mesenchymal stem cells. This system had flexural strength of 26 MPa,
while calcium phosphate cement control was 10 MPa. In addition, an excellent and higher
viability of human umbilical cord mesenchymal stem cells was obtained with scaffolds using
chitosan fibers than those controls without fibers. Human umbilical cord mesenchymal stem
cells had excellent proliferation (300 and 700 cells/mm2 on 1 and 4 day, respectively) and
viability on the scaffolds [222]. A study showed that the chitosan surface modified with
fructose (ligand of asialo-glycoprotein receptor in hepatocyte) on porous chitosan scaffolds
induced the formation of cellular aggregates and enhanced liver specific metabolic activities
and cell density to a satisfactory level [223, 224]. Chitosan microfibers were also developed
and coated with collagen. Schwann and fibroblast cells were cultured on the chitosan micro‐
fibers to be adhered to the surface of the systems. After 72 h, the Schwann cells had proliferated
linearly while the fibroblast cells covered the surface of the chitosan microfibers. The chitosan
microfibers provide very good scaffolds for many tissue engineering applications with the
advantages of ease of fabrication, simplicity and cost effectiveness [225].
5. Uptake and endocytic pathway of chitosan
One of the most important routes to drug delivery is the oral pathway. The uptake of chitosan
into the bloodstream is generally not investigated in oral administration studies. Chitosan's
systemic absorption and distribution from this route of delivery may be largely dependent on
the Mw. It is very likely that oligomers could show some absorption whereas larger Mw
chitosans are excreted without being absorbed. This effect was seen with FITC-labeled
chitosans with 3. 8 kDa (88. 4% degree of deacetylation) chitosan having the greatest plasma
concentration after oral administration vs 230 kDa (84. 9% degree of deacetylation) having
almost no uptake. Increasing Mw was seen to decrease the plasma concentration in this, one
of the only studies investigating plasma concentration after oral administration [226]. Tri‐
methyl chitosan oligomers/DNA nanoparticles were taken up in the gastric and duodenal
mucosa and to some extent in the jejunum mucosa, ileal mucosa and large intestinal mucosal
cells as shown by green fluorescent protein (GFP) expression [227]. Chitosan polymers are not
absorbed by the gastrointestinal way and are unlikely to show biodistribution. Chitosan
oligosaccharides however may be absorbed to some extent.
Although native chitosan has not been investigated, the intracellular uptake and distribution
of chitosan/DNA complexes have been studied in vitro [228–230]. Chitosan polyplex uptake
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at 37 °C was 3-fold higher than at 4 °C [228] but this could be due to increased interaction and
not an ATP dependent endocytic mechanism. The authors suggested nuclear localization and
they also stated little dissociation of the DNA from the chitosan. In a more comprehensive
study, Leong et al. stained for lysosomes and found some co-localization with chitosan DNA
nanoparticles. However, the majority of the polyplexes were found in the cytosol [229]. A
complex of doxorubicin with chitosan has also been studied; complexes enter cells through an
endocytic mechanism which was not further elucidated [231]. Hydrophobic (5-β-cholanic acid)
modified glycol chitosan nanoparticles were internalized into HeLa cells through all the
endocytic mechanisms studied: clathrin coated vesicles, caveolae and macropinocytosis. This
study agrees with that of Leong, in that some particles were lysosomal but most were not [232].
Unfortunately, these studies all involve nanoparticle uptake of relatively large (>100 nm)
nanoparticles or aggregates of complexes and not just labeled chitosan. Dodane and Vilivalem
reported that chitosan has membrane perturbing properties that do not decrease cell viability
[233]. It is likely that chitosan and chitosan nanoparticles enter the cell via cell membrane
perturbation due to the cationic charge. It is important to understand chitosan's cell trafficking
and investigate both endocytosis and exocytosis. Such study should shed some light on
chitosan's biocompatibility.
It is important to mention that cellular uptake kinetics may be altered due to the charge
interaction (e. g. in the case of DNA complexes). This balancing, or reduction, of the positive
charges on the chitosan molecule has effects on its interaction with cells and the microenvir‐
onment, often leading to decreased uptake and a decrease in toxicity. In the case of a covalent
drug conjugate, the polymer's physicochemical properties (hydrophilicity) and conformation
are altered (i. e. micelle formation) with a consequent effect on distribution and cell uptake [52].
Similar results were found for poly(dl-lactic-co-glycolic acid) nanospheres surface modified
by adsorption of chitosan for pulmonary administration, which were preferentially taken up
by human lung adenocarcinoma cells (A549) in a temperature dependent manner [234].
Moreover, cellular uptake of these nanocarriers increased with decreasing diameter to the
submicron level and the cellular uptake of nanospheres were promoted through electrostatic
interactions between the surface due to chitosan adsorbed and the negatively charged cell
membrane without showing cytotoxicity. Internalization of nanospheres (200-nm) by A549
cells appears to occur predominantly through adsorptive endocytosis initiated by nonspecific
interactions between nanospheres and cell membranes, and is partially mediated by a clathrin-
mediated process. Thus, chitosan is suitable as a material for surface modification of systems
for intracellular targeting because it could increase the interaction between the cell membrane
and the systems [234]. The effect on the charge of the systems was also reported for a large
array of N-(2-hydroxypropyl)methacrylamide (HPMA) based copolymers, which were
internalized into the prostate cancer cells through multiple endocytic pathways: positively
charged copolymers robustly engaged clathrin-mediated endocytosis, macropinocytosis and
dynamin-dependent endocytosis, while weakly negatively charged copolymers weakly
employed these pathways; strongly negatively charged copolymers only mobilized macropi‐
nocytosis [235].
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The hydrophobicity of the systems as drug delivery vehicles for therapeutic applications is
another physicochemical property which has been investigated on the cellular uptake. Here,
a hydrophobic glycol chitosan system (5β-cholanic-acid conjugated glycol chitosan) was
reported to show several distinct uptake pathways involved in their internalization with a
single degree of substitution [232]. Moreover, different degree of substitution (or hydropho‐
bicity) could affect the endocytosis of hydrophobically-modified polymers. The cellular uptake
of nanoparticles prepared by a hydrophobically-modified chitosan (N-palmitoyl chitosan),
was significantly enhanced with increasing the degree of substitution. The internalization of
these systems was clearly related with the lipid raft-mediated routes. With increasing the
hydrophobicity on polymer, the caveolae-mediated endocytosis became more important. The
internalized nanoparticles transiently associate with CAV1 at cell membranes and at a
peripheral CAV1- positive structure coupled with caveosomes before trafficking to the
endosomal pathway [236].
In addition, the cell entry and subsequent intracellular trafficking of drug carriers using
chitosan or a combination with another polymer are strongly dependent on their physico‐
chemical characteristics, such as charge and molecular weight. In addition, the route of
administration determines the uptake, concentration, contact time and cell types affected [52].
6. Advantages and limitations over other pharmaceutical systems for non
parenteral routes
6.1. Advantages
Chitosan  is  one  of  the  most  promising  polymers  because  of  its  nontoxic,  polycationic,
biocompatible,  and biodegradable  nature  and particularly  due  to  its  mucoadhesive  and
permeation-enhancing properties [237-239]. Moreover, the strong mucoadhesive property of
chitosan is most important for drug delivery through the mucosal routes. In addition, the
interaction of the positively charged chitosan with the negatively charged mucin layer and
the tight junctions facilitates the paracellular transport of hydrophilic macromolecules by
opening the tight junctions of the mucosal barriers [111, 239-242]. Additionally, chitosan is
cheap [243]. Practical use of chitosan has been widely investigated due to its ability to form
hydrogels, to its biocompatibility in physiological environments (enzymes chitosanase and
lysozyme degrade chitosan and form harmless products), enhancing it with deacetylation
reactions. Moreover, its biocompatibility was demonstrated with viable cartilage producing
any untoward effect [216].
One of many investigations using chitosan is as vaccines vehicles, which have showed better
efficacy than the approved injectables (induce strong systemic immune responses and
represent a pharmaceutical form painful). Diverse chitosan microspheres have been evaluated
for controlled drug release and to enhance the protection and permeation of the antigens in
the nasal mucosa, inducing antigen specific immune responses in both the nasal mucosa and
the systemic compartment [114, 115, 196, 197]. Besides, the induction site of the antigen-specific
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mucosal immune responses were found contained in a broad range of mucosal surfaces (nasal
and vaginal routes and the salivary gland).
Several studies have been conducted on chemically modified chitosan systems through their
concomitant use with adjuvants for a synergistic effect, and through the mannosylation of
chitosan for target the receptor-mediated. The chemically modified chitosan systems combined
with other adjuvants have showed to have an increased immunostimulatory in nasal vaccine
delivery [114, 115]. Another advantage of chitosan formulations is its cationic property, which
has been also exploited to deliver a tissue plasminogen activator to substrates of the fibrin
network or insulin to mucosa surfaces [244, 245]. Nasal delivery of insulin from solutions and
gels based of chitosan incremented greatly the permeability and transmucosal absorption,
which could avoid the pain and inconvenience of injections of insulin in patients [246, 247).
Moreover, in vitro insulin delivery using gels of chitosan, glutaraldehyde, Pluronic F-127/F-68
and glycine significantly reduced the burst release of insulin and sustained the release of it for
up to 20 h, suggesting that such gels are potentially effective carriers of insulin for nasal
delivery [247].
Systems based in chitosan can provide advantages by their mucoadhesive properties overcome
to the conventional formulations such as those for via ophthalmic, that are eliminated from
the precorneal area immediately upon instillation because of lacrimal secretion and nasola‐
crimal drainage, needing a frequent instillation of concentrated solutions to achieve the desired
therapeutic effects [248, 249]. In order to lengthen the resident time of instilled dose and
enhance the ophthalmic bioavailability various conventional and non conventional (colloidal
drug delivery systems, such as liposomes, biodegradable nanoparticles and nanocapsules)
ophthalmic vehicles based in chitosan have been developed, but their use is reduced due to
some adverse effects such as blurred vision from ointment or low patient compliance from
inserts [250]. In order to avoid the blurred vision, a combination of chitosan and Pluronic F-127
could be used for the preparation of in situ forming gels with improved mechanical and
mucoadhesive characteristics for prolonged precorneal residence time in vivo [251].
Mucoadhesive properties are also important for the buccal administration, which involve the
direct entry of the drug into the systemic circulation avoiding the first pass hepatic metabolism.
This route is easily accessible for self medication where the drug can be easily administered
or if necessary, removed from the site of application. In order to maintain the device in its
position for many hours against buccal motion and salivary flow, which could reduce the
mucosal absorption, the dosage form must have good adhesive properties and show an
efficient control of drug delivery. These characteristics have been obtained with systems using
chitosan alone, modified chitosan, chitosan mixed with other components such as, sodium
alginate or using chitosan glutamate proposed for bilaminated films and bilayered tablets [117,
118, 164]. In adittion, chitosan has the potential to be a safe pharmaceutical excipient for non-
parenteral drugs. Altohoug it was approved for dietary applications in Japan, Italy and Finland
and it has been approved by the FDA for use in wound dressings, more studies must be
performance to ensure its safety. In Table 6 summarizes mains advantages in applications of
chitosan systems by use other components.
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Materials Applications References
Chitosan and carmomer Improved oral bioavailability of buserelin. [141]
Chitosan and PEGylated 3. 4-fold was improved its mucoadhesive properties of chitosan. [142]
Preactivation of thiol groups on chitosan via the
formation of disulfide bonds with
mercaptonicotinamide
Mucoadhesive properties of thiolated chitosans were even significantly
improved.
[143]
Chitosan and poly(g-glutamic acid) and chitosan
and polyacrylic acids
This combination could be infiltrated in the cell–cell junctions and interact
with Helicobacter pylori infection sites for the treatment of peptic ulcer.
[252]
Modified chitosan hydrogels loaded with
metronidazole, tetracycline and theophylline
Modified chitosan hydrogels loaded with metronidazole, tetracycline and
theophylline could bypass the acidic environment of the stomach and
release the loaded drug into the intestine
[252]
Chitosan and thiolated chitosan Chitosan and thiolated chitosan are used to improve the oral bioavailability
of acyclovir 3-fold and 4-fold.
[148]
Chitosan with glutaraldehyde or ethylene glycol
diglycidyl
Chitosan with glutaraldehyde or ethylene glycol diglycidyl are used to load
antibiotics.
[174]
Chitosan microspheres reacetylated with acetic
anhydride
The re-acetylated chitosan microspheres were able to interact closely with
the gastric mucosa and to exhibit sustained delivery of entrapped antibiotic
[175]
Clozapine-loaded nanoparticles with chitosan
and polysorbate 80
A great improvement in surface hydrophilicity was brought by chitosan and
polysorbate 80 coatings
[176]
Pectin/chitosan/hydroxypropyl methylcellulose
(3 : 1: 1)
This formulation had reached the colon [174]
Chitosan and pluronic F-127 Drug release systems for via buccal was improved and demonstrating that
independently of chitosan salt type (citrate, acetate and lactate),
mucoadhesion was significantly favoured when the concentration of
Pluronic F-127 in the matrix was about 30% (w/w).
[175]
Trimethylated chitosans Sandri et al. (2005) showed that trimethylated chitosans seem to be
promising exipients for drug delivery systems intended for buccal mucosa
applications to enhance the absorption of hydrophilic macromolecules.
[169]
Chitosan hydrogel beads coated with enteric
polymer Eudragit S 100
Chitosan hydrogel beads coated with enteric polymer Eudragit S 100 to be
targeted to the colon, prevented premature drug release in simulated
gastric fluid, but delivered in the colon, because chitosan was degraded by
the bacterial enzymes.
[159]
Chitosan with gelatin Huang et al. (2005) blended chitosan with gelatin to improve the biological
activity.
[177]
Chitosan with poly(ε-caprolactone) These blending membranes improved mechanical properties as well as
cellular support.
[178]
The γ-poly (glutamic acid) (γ-PGA) a hydrophilic
and biodegradable polymer
This formulation was also used to modify chitosan matrices and the γ-PGA/
chitosan composite matrix was found to enhance hydrophilicity and serum
proteins adsorption, and to increase the maximum strength through
addition of γ-PGA in tissue engineering applications.
[179]
Chitosan and PLGA Yamamoto et al. showed that chitosan-coated PLGA nanoparticle
suspensions improved the absorption of calcitonin after pulmonary
administration.
[187]
Chitosan-coated gold nanoparticles Chitosan-coated gold nanoparticles have been investigated for mucosal
protein delivery.
[253]
Chitosan nanoparticles with cyclosporine A Chitosan nanoparticles with incorporated cyclosporine A in improving the
delivery of drugs to the ocular mucosa.
[127]
Table 6. Main advantages in applications of using of chitosan with different materials.
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6.2. Disadvantages
Several limitations of the systems using chitosan alone, modified chitosan, or chitosan mixed
with other components could be mentioned. One of the most important is the general rapid
clearance of the formulations in the mucosal surface owing to the mucociliary clearance and
the presence of a variety of metabolic enzymes (cytochrome P-450 enzymes, conjugative Phase
II enzymes, nonoxidative enzymes, and proteolytic enzymes that could reduce the absorption)
of drugs administered via nasal using conventional chitosan formulations [254]. Nonetheless,
these limitations are reduced when the drugs are entrapped in micro or nanoparticles using
chitosan and other components.
Chitosan, has shown a hypoglycemic effect in streptozotocin (STZ)-induced diabetic animals
[255- 257]. Other studies also found that low molecular weight chitosan (average MW about
2. 0 x 104 Da) as well as chitosan oligosaccharides can reduce plasma glucose level in diabetic
animals [258, 259]. On the other hand, when chitosan is used as a coat in liposomes, it helps in
delaying intestinal transit time so as to increase absorption of insulin. An increase in chitosan
molecular weight caused increase in the hypoglycemic efficacy of chitosan-coated insulin
liposomes. The hypoglycemic efficacy of the liposomes coated by chitosan 1000 kDa was
markedly superior to that of the liposomes coated by other chitosans. Both increasing and
decreasing chitosan concentration, the hypoglycemic efficacies of chitosan-coated insulin
liposomes were decreased and the systems were not able to protect insulin from enzymatic
digestion [260]. Thus, diabetic patients should be careful when administering chitosan if they
not eating above.
Chitosan systems have limited applications in drug delivery and tissue engineering due to
their hydrophilic nature and insolubility in certain physiological conditions (eg. blood-brain
barrier), due to chitosan is soluble at pH values below 6. 5 [261]. Besides its mucoadhesive and
controlled release properties chitosan is also able to increase the paracellular permeability due
to the opening of tight junctions which has been shown for various routes of delivery such as
for nasal or intestinal drug delivery. However, no effect on the paracellular permeability could
be observed at pH 7. 4, which is the physiological pH of blood [262]. This indicates that chitosan
solutions are not effective as permeation enhancer at neutral pH values, because of the missing
solubility of chitosan at neutral and alkaline pH values. Chitosan in form of particles can
overcome this problem, because particles need not to be dissolved.
It is important to mention that the modification of the polymer can change the properties of
the systems. Chitosan can be readily modified by reactions at the amino and hydroxyl groups
present in the molecule, but adequate optimizations of the formulations need to test, increasing
costs, time, and toxicological studies. It is important to mention, that some derivatives increase
in toxicity and any residual reactants must be carefully removed [51]. Additionaly, studies of
in vivo and in vitro biodistribution and toxicity, using various chitosans of different molecular
weights and degrees of deacetylation and derivatives would provide data that could help
correlate chitosan's structure and safety profile [50]. Further studies needs to be conducted in
this sense in order to approved based chitosan systems.
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7. Conclusion
Potential applications of chitosan as weight supplement in the market as well as drug carrier
in pharmaceutical formulations and as an important material able to prepare regenerative
structures for bones and cartilages have been investigated. Thus, this work summarizes recent
pharmaceutical developments using chitosan, modified chitosan or mixes with other compo‐
nents as drug carriers for the most non parenteral routes of administration including oral,
topical, intranasal, and ocular, etc. Various therapeutic agents, such as anticancer, anti-
inflammatory, antibiotics, antithrombotic, steroids, proteins, amino acids, antidiabetic and
diuretics have been incorporated in chitosan-based systems as carriers to improve the
dissolution rate of poorly soluble drugs and to achieve controlled release. Although, chitosan
systems have limited applications in drug delivery and tissue engineering due to their
hydrophilic nature and insolubility in certain physiological conditions (eg. blood-brain barrier)
due to chitosan is soluble at pH values below 6. 5, chitosan particulate systems can be used as
carriers for encapsulate drugs and to enhance their bioavailability and delivery. The primary
amines of chitosan impart these valuable physicochemical properties including particular
interactions with cells, proteins and living organisms. On the other hand, the safety of chitosan
could also be achieved in shellfish allergic patients since it was shown that the subjects have
tolerated the polymer without reaction demonstrating the safety of other chitin-derived
products in patients allergic to shellfish. Since chitosan has the hydroxyl and amino functional
groups, important results have been obtained by reacting chitosan with controlled amounts
of multivalent anions (functional groups) to control hydrophobic, cationic and anionic
properties enhancing the vectorization, the stability, and the mucoadhesively (to prolong the
drug residence time) of the drug carrier systems. These properties of chitosan, especially their
intrinsic antibacterial activity, their ability to bind anionic molecules such as growth factors,
glucosamine glycans and DNA and their ability to be processed into a variety forms are also
used to generate suitable structures for bone and cartilage regeneration. However, more
studies to improve their mechanical properties are essential for this type of application.
Although many successful systems of chitosan have been developed, more toxicity tests must
be conducted in order to ensure their safety when it is incorporated in other systems.
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